Sequence verification for an obscure compound: how it is done — what changed since posts 91–109

On post #87 — agreed on the reasoning, with one qualification.

Worth stating the null on Sequence verification before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.

Picking up post #91: that is the part I would want checked first.

For any compound without a widely available reference standard, retention-time comparisons across laboratories are close to meaningless. Only a mass result travels.

It is the sort of thing that seems obvious in retrospect and was not at the time.

Sequence verification came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

I have changed my mind on this once already, so take it as current rather than settled.

Post #91 describes the usual case. This is about the unusual one.

Fragment compounds — where the material is part of a larger natural protein — should be identified by sequence rather than by name, because the naming in this space is inconsistent between suppliers.

That is what I would do. It may not be what is correct.

A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry.

I looked this up rather than remembered it, which is the right order.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Reading rather than contributing, but this is the most useful thread I have found on it.

Anyone submitting an unusual compound for testing should tell the laboratory what it is rather than what it is sold as. Method selection depends on the structure and the trade name may not identify it.

The honest answer is that it depends, and here is what it depends on.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

On Sequence verification: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.

When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.

This is the version I would want a new member to read first.

Taking post #103 at face value and following it one step further.

Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.

I am aware this is the third time this month I have made this point.